ALB and anemia: Pretreatment factors such as advanced stage of disease (Stage IIB, IIIB, or IV), presence of B symptoms, histology, presence of bulky disease, extranodal extension, elevated erythrocyte sedimentation rate, leukocytosis (WBC count of ≥11.5x103/μL), anemia (hemoglobin of <10.5-11.0 g/L), male sex, rapidity of response to initial treatment with chemotherapy, fluorodeoxyglucose-PET avidity after two cycles, low serum albumin (<4 g/dL), and low lymphocyte count (<0.6x103/μL or <8% of WBC count) were reported as prognostic factors in previous studies [8,9,10,11,12,30].